UNLEASHING THE POWER OF RESEARCH

Exploring new frontiers in glioblastoma research to overcome challenges for patients worldwide

Welcome to the Glioblastoma Research Society

We are dedicated to advancing scientific knowledge and improving patient's lives through groundbreaking research

Our Vision

The Glioblastoma Research Society envisions a world where scientific knowledge and medical innovation are accessible to all and have the potential to transform lives. We are committed to advancing our understanding of glioblastoma and driving progress through bold research, innovation and discovery.

A B O U T G L I O B L A S T O M A R E S E A R C H S O C I E T Y

Our Approach

Our approach to research is interdisciplinary and collaborative, bringing together experts from different fields to tackle the current challenges we face in treating glioblastoma tumors. We fund projects that have the potential to make a significant impact in patients' lives and support researchers throughout the entire process.

Our Partnerships

At the Glioblastoma Research Society, we believe that collaboration and partnerships are essential to driving progress and advancing scientific research. By bringing together young investigators, research institutions and donors like you, we can continue to accomplish our mission through accelerating the pace of discovery.

GBM

Glioblastoma, also known as glioblastoma multiforme (GBM), is a fast-growing and extremely aggressive brain tumor most often found in the cerebral hemispheres, especially the frontal and temporal lobes. It is categorized as a grade IV astrocytoma, which quickly invades surrounding brain tissue and can also spread to the spinal cord. GBM is the most common type of primary malignant brain tumor, accounting for 48% of all cases.

Our Project

Over the next three years, we will be combining patient data with pre-clinical disease models to identify factors and cellular pathways that drive the treatment resistance and regrowth of GBM tumors. This will then allow us to develop road blocks to the establishment and proliferation of GBM, as well as to increase tumors' responsiveness to treatment. This internationally collaborative endeavor requires a budget of $1.5M to complete.

A B O U T G L I O B L A S T O M A M U L T I F O R M E

Survival

The median age of diagnosis is 64, after which patients can expect to survive 14–16 months on average. GBM's prognosis is exceptionally poor; only approximately 30% of patients can expect to survive the first year post diagnosis and a mere 14% the second year. The five-year survival rate is less than 5%. About 200,000 people die from GBM each year, including nearly 15,000 in Europe and 9,000 in the US.

an abstract photo of a curved building with a blue sky in the background

My mom faced glioblastoma with incredible strength. She fought with everything she had, but we lost her in just 11 short months. Supporting the Glioblastoma Research Society gives me hope that one day, families like mine will have more time—and better options.

Pricilla Freschu, MSc, Science Writer

Cancer research has made enormous progress, but glioblastoma remains one of the toughest challenges. The Glioblastoma Research Society funds bold, innovative science aimed at changing this. If we want real breakthroughs, we have to support the researchers willing to take them on.

Pauline Gately, Caregiver

When I learned that my tumor had recurred and that this time, chemo would most likely be ineffective, it made me realize just how important the work being done by the Glioblastoma Research Society truly is.

Jean Marie Atelier, Glioblastoma Patient

Mehdi Touat, MD, PhD

Principal Investigator, Paris Brain Institute Neuro-Oncologist, Hôpital Pitié-Salpêtriére

G L I O B L A S T O M A R E S E A R C H S O C I E T Y F O U N D I N G M E M B E R S

Franck Bielle, MD, PhD

Principal Investigator, Paris Brain Institute Neuropathologist, Hôpital Pitié-Salpêtriére

Sylvain Provot, PhD

Vice President

Learn more

Líza Willey, MSc

Líza has been conducting scientific and medical research in academia and industry for almost a decade. She received her Masters of Science degree in Cell & Molecular Biology at Sorbonne University in Paris. Her research and teaching career has spanned the fields of Neuroscience, Stem Cell Biology, Immunoncology and Developmental Biology. Her work at UCSF, UC Berkeley, Pfizer and Maze Therapeutics has helped to advance the understanding and treatment options of many diseases including GBM, Alzheimer's Disease, ALS, Breast Cancer, AML, and Infertility. Passionate about neuroscience, she is currently pursuing her PhD in neurobiology at Sorbonne Université.

President

Principal Investigator, Hôpital Lariboisiére Professor, Université Paris Cité

Chief Operating Officer

Advisory Board Member

PhD Candidate, Sorbonne Université Doctoral Researcher, Paris Brain Institute

Learn more

J o i n O u r C a u s e

DONATE TODAY

Your donation directly helps advance brain cancer research and brings us closer to finding solutions to some of its biggest challenges.

Join the fight against brain cancer today!

GRS is a 501(c)(3) organization; all donations are 100% tax deductible

TELL US YOUR STORY

How has GBM affected you or a loved one? Tell us about your experience with this devastating disease and what your hopes are for the future of research.